Meta-analysis shows fewer complications and higher occlusion rates for ruptured wide-neck intracranial aneurysms, using Rapid Medical’s COMANECI™ Embolisation Assist Device
19 July 2023: Rapid Medical™, developer of advanced neurovascular devices, has announced new clinical data showing significant advantages of its novel COMANECI™ embolisation assist device over established techniques to treat ruptured wide-neck intracranial aneurysms. A recent meta-analysis published in World Neurosurgery found that COMANECI is associated with lower haemorrhagic and thromboembolic complication rates, higher complete occlusion rates, and similar residual retreatment rates than stent-assisted and balloon-assisted coiling techniques.
As the only adjustable, non-occlusive device for haemorrhagic stroke treatment, COMANECI’s visible mesh conforms to the anatomy, providing stent-like support without the complications of a permanent stent or halting blood flow like a balloon. It has been used in over 12,000 procedures worldwide in wide-neck aneurysm treatments–and in Europe only–to open arteries constricted by vasospasm.
Researchers at the University at Buffalo and George Washington University compared the three devices by pooling over 3200 ruptured aneurysms across 64 studies. No significant differences were found between SAC and BAC. However, COMANECI-assisted coiling showed significantly lower thromboembolic and aneurysmal complication rates and periprocedural complications – than both SAC and BAC. Furthermore, COMANECI demonstrated statistically better complete occlusion rates than SAC and equivalent rates to BAC.
The COMANECI device is a highly useful adjunct tool for patients with subarachnoid haemorrhage. While stent-assisted coiling (SAC) and balloon-assisted coiling (BAC) are widely used therapies, each method has unique drawbacks that are nicely addressed with the COMANECI device
Study author Adnan Siddiqui, MD, PhD, Vice-Chairman and Professor of Neurosurgery of the University at Buffalo and CEO of the Jacobs Institute
